Stay updated with breaking news from Dyno Capsidmap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Dyno Therapeutics Inc. said that they have reach an agreement to develop next-generation adeno-associated virus or AAV vectors for gene
Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration May 11, 2021 Share Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen. The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed to combine Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform and associat...
Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing. The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen Horowitz, joined the company’s board of directors. Led by Eric Kelsic, PhD, founder and CEO, Dyno T...